Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors
*Trial for liver mets
*Talimogene laherparepvec (T-VEC) injected intrahepatically, into liver tumors, included metastases from CRC.
*Several locations: California, Kentucky, Missoury,New Jersey, Spain, Switzerland.
*Liver tumors must not be estimated to invade approximately more than one-third of the liver.
*Must have measurable liver tumors that are suitable for injection.
*Adequate hematological, renal, hepatic and coagulation function is required.
More info on the trial page https://clinicaltrials.gov/ct2/show/NCT02509507
Important: T-VEC is an APPROVED, SINCE 2015, IMMUNOTHERAPY FOR MELANOMA LESIONS. Very well known agent.
IMLYGIC® (talimogene laherparepvec) was the first oncolytic viral therapy approved in US, in 2015, for melanoma. Intratumoural injection on lesions.
"Talimogene laherparepvec (T-VEC) produced (Amgen) is a drug created from a genetically modified herpes virus, allowing it to not only directly attack the cancer cell, but to change the DNA of a tumor cell as well. The genetic modification to the tumor causes it to excrete a continuous stream of GM-CSF, an immune system "emergency signal." This attracts T-cells to the tumor in large numbers for as long as the tumor exists. As a treatment T-VEC has an impressive safety profile."